CNBC June 17, 2020
Key Points
– Tempus was formed to help identify cures for a variety of illnesses, from cancer to depression and now Covid-19.
– The health-care company conducts genomic tests and analyzes clinical data in a patient’s electronic health-care records, anything from medical imaging to a doctor’s handwritten notes.
– Former FDA Commissioner Scott Gottlieb is on the Tempus board of directors, and the company is valued at $5 billion by investors.
– The company made the CNBC 2020 Disruptor 50 list, revealed Tuesday.
Tempus, a Chicago-based technology company that offers genetic testing and aggregates clinical information, initially focused on cancer patients. But with the coronavirus pandemic spreading across the world, it’s joining the fight against Covid-19.
Tempus was founded in...
Today's Sponsors
Today's Sponsor